There’s a new neurotoxin making its debut in the aesthetic market! Evolus, the company behind this new drug, is the first company to enter the facial aesthetics market in over a decade.
Jeuveau is an FDA approved neurotoxin used for the treatment of glabellar lines or the frown lines that appear between your eyebrows. It works by preventing nerves from telling the facial muscles to flex. Jeuveau is made with a modern manufacturing process using Hi-Pure technology.
The FDA approval was based on two major clinical trials. After 30 days, 67.5% of subjects in one study, and 70.4% of patients in a second study met the primary endpoint, a 2-point composite improvement agreed upon by physician and patient. This was compared to 1.2% and 1.4% of patients who received the placebo.
The most commonly reported side effects from the clinical trials included headache, eyelid drooping, upper respiratory tract infection, and increased white blood cell count. There were no serious drug-related adverse events reported in the studies. As with any injection, a patient may still experience pain, infection, inflammation, tenderness, swelling, erythema, and/or bleeding/bruising around the injection site. The results of Jeuveau are temporary and patients reported receiving 3 treatments over the course of 1 year.
The company is focusing on targeting millennials with its digital platform that enhances the beauty experience of users. According to the website, Evolus says, ”We’re giving the aesthetics process a modern-day makeover, thanks to an open communication style and updated technology.” With the rise in aesthetic patients and procedures, it’s great to have another tool in your tool belt. This product is another option to add to your arsenal of treatments for your patients, depending on your patient’s needs and expectations.